# Janux Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/janux-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.januxrx.com/
- Total disclosed funding: $181M
- Latest round: Series B (Apr 15, 2021)
- Investors on record: 12

## About

Founded in 2017 and based in California, US, Janux Therapeutics, Inc. operates as a biotechnology company that develops immunotherapies for cancers. The company was founded by President and CEO David Campbell. In February 2024, JANUX Therapeutics raised USD 296.5 million in a private placement, selling 4.44 million shares at USD 46.50 per share, on the Nasdaq Global Select Market under the ticker symbol "JANX". Janux Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 956,450 shares of common stock as part of the listing. In December 2024, Janux Therapeutics, Inc. raised USD 349.99 million in a private placement, selling 5.31 million shares at USD 63 per share, on the Nasdaq Global Select Market under the ticker symbol "JANX". Janux Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 833,333 shares of common stock as part of the listing.

Janux Therapeutics is a biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology that treats patients suffering from cancer. Janux Therapeutics focuses on developing a novel class of T cell engagers (TCEs), and its product candidates designed to target clinically validated drug targets. The company's TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developed to treat solid tumors and faced challenges due to the limitations of prior technologies, namely (I) overactivation of the immune system leading to cytokine release syndrome, (II) on-target, healthy tissue toxicities, and (III) poor pharmacokinetics leading to short half-life. Janux is also developing pipelines with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2).

The company plans to support the advancement of its pipeline T cell engager immunotherapies, including a PSMA-TRACTr, EGFR-TRACTr, and TROP2-TRACTr, into initial proof of concept clinical trials.

## Funding rounds

- Series B, Apr 15, 2021, $125M — OrbiMed Advisors, Avalon Ventures, BVF Partners, RA Capital Management, EcoR1 Capital, Bregua Corporation, Janus Henderson Investors, Samsara BioCapital, Surveyor Capital, Hartford HealthCare Corporation, Logos Capital
- Series A, Mar 1, 2021, $56M — OrbiMed Advisors, Avalon Ventures, Correlation Ventures, RA Capital Management, Bregua Corporation

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series A, Series B
- Correlation Ventures (https://capitalatlas.ai/funds/correlation-ventures) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- Bregua Corporation — Series A, Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Janus Henderson Investors — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Surveyor Capital — Series B
- Hartford HealthCare Corporation — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B